Disease relevance of Nortrip

• A randomized, double-blind trial assessing the efficacy and safety of sublingual metopimazine and ondansetron in the prophylaxis of chemotherapy-induced delayed emesis [1].

High impact information on Nortrip

• Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy [2].
• Ondansetron plus metopimazine compared with ondansetron plus metopimazine plus prednisolone as antiemetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapy [3].
• This randomized, double-blind, double-dummy parallel study compared the anti-emetic efficacy and tolerability of the serotonin antagonist granisetron with prednisolone plus the dopamine D2 antagonist metopimazine during nine cycles of moderately emetogenic chemotherapy [4].
• Bioavailability of the antiemetic metopimazine given as a microenema [5].
• The "in vitro" transdermal absorption characteristics of various antiemetic drugs (Alizapride, Bromopride, Clebopride, Domperidone, Metoclopramide, Metopimazine) were studied [6].

Chemical compound and disease context of Nortrip

• The incidence of complete response (defined as no nausea and emesis for 5 days) did not differ between the two treatment arms (53.4% for metopimazine versus 49.5% for ondansetron; P=0.58) [1].

Anatomical context of Nortrip

• Effects of metopimazine on gastro-intestinal and biliary tract smooth muscle in vitro [7].

Analytical, diagnostic and therapeutic context of Nortrip

• Serum concentrations of metopimazine and the acid metabolite AMPZ were measured by HPLC in 13 patients (15 cycles) [8].
• Two controlled double-blind studies were carried out successively on a cancerous out-patient population receiving multiple combination chemotherapy at successive treatment courses to show the anti-emetic efficiency of metopimazine compared to a placebo [9].

References